《新股消息》清晰醫療(01406.HK)公開發售超購逾5倍及下限定價 一手中籤率40%
眼科專科醫療機構清晰醫療(01406.HK)公布招股結果,每股發售價定為1.6元,為招股價範圍(1.6至3元)下限定價。香港公開發售部分錄得超額認購5.17倍。該股將於明日(18日)掛牌,每手1,250股計,一手中籤率為40%,認購8手即1萬股可穩獲一手。獨家保薦人為光大國際。
公司是次上市料淨集資約1.77億元,約44.8%擬用於在香港成立兩家新醫療中心以提供眼科服務;30.5%用於收購大灣區內選定城市的一至兩家眼科診所、眼科門診部或眼科醫院的多數及/或少數權益;14.7%用於與合適的合作夥伴在中國設立眼科診所以提供眼科醫療服務;10%用於營運資金及其他一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.